The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study - Trial NCT06375304
Access comprehensive clinical trial information for NCT06375304 through Pure Global AI's free database. This Phase 4 trial is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre and is currently Not yet recruiting. The study focuses on HIV Infections. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
McGill University Health Centre/Research Institute of the McGill University Health Centre
Timeline & Enrollment
Phase 4
May 01, 2024
May 01, 2027
Primary Outcome
Feasibility of the switch,Acceptability,acceptability of the regimen,Acceptability of the intervention,Fidelity
Summary
This project builds on our experience with the ASAP Study (McGill University Health Centre
 research ethics board: MP-37-2020-4911). The goal of this study is to better understand the
 experience of migrant people with Human Immunodeficiency Virus (HIV) of having their
 treatment switched to Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). In other
 words, the investigators want to evaluate how feasible and acceptable this switch is, and how
 participants will take B/F/TAF (fidelity) and remain on it. The investigators also want to
 know more about migrant people with HIV's experience of care; namely, how often they see
 their HIV specialist or other healthcare professionals, and their healthcare coverage (the
 type of insurance that they have).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06375304
Non-Device Trial